itraconazole

Trade name: sporanox

Small moleculeapproved

Approved

Sep 11, 1992

SPORANOX is the brand name for itraconazole, an azole antifungal agent. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers. In vitro studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis. SPORANOX capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary; Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. SPORANOX is also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Itraconazole is mainly metabolized through CYP3A4. Other drugs that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of itraconazole. Similarly, itraconazole may modify the pharmacokinetics of other drugs that share this metabolic pathway. Itraconazole is a potent CYP3A4 inhibitor and a P-glycoprotein inhibitor. When using concomitant medication, it is recommended that the corresponding label be consulted for information on the route of metabolism and the possible need to adjust dosages. — NCATS

Clinical trial activity

409 trials · 246 clinical orgs · 21 marketing orgs

Phase 1
319
Phase 2
56
Phase 3
20
Phase 4
16

Earliest trial started Mar 1, 1985 (NCT00004811)

Timeline

1980s

  1. Jan 1, 1985

    Earliest Phase 1 Sponsor(trial)

1990s

  1. Jan 1, 1991

    Earliest Phase 2 Sponsor(trial)

  2. Sep 11, 1992

    Johnson and Johnson — Earliest FDA Approval

  3. Sep 11, 1992

    Johnson and Johnson — NDA Organization

  4. Dec 6, 1996

    Johnson and Johnson — NDA Secondary Org

  5. Jan 1, 1998

    Earliest Phase 3 Sponsor(trial)

2000s

  1. May 28, 2004

    Sandoz — Marketing Organization

  2. May 28, 2004

    Novartis — Marketing Organization

2010s

  1. Apr 29, 2010

    Sebela Pharmaceuticals — NDA Secondary Org

  2. Jul 20, 2012

    Mylan — Marketing Organization

  3. Oct 30, 2015

    Amneal Pharmaceuticals — Marketing Organization

  4. May 26, 2016

    Accord Research — Marketing Organization

  5. Dec 13, 2016

    Alembic — Marketing Organization

  6. Dec 13, 2016

    Par Pharmaceuticals — Marketing Organization

  7. Dec 13, 2016

    Bristol-Myers Squibb — Marketing Organization

  8. Dec 13, 2016

    Rising Pharmaceuticals — Marketing Organization

  9. Feb 23, 2017

    Jubilant Innovation Ltd. — Marketing Organization

  10. Jun 12, 2017

    Alkem Labs Ltd — Marketing Organization

  11. Sep 19, 2017

    Zydus Discovery DMCC — Marketing Organization

  12. Aug 24, 2018

    Torrent Pharmaceuticals Limited — Marketing Organization

  13. Dec 11, 2018

    Mayne Pharma — NDA Secondary Org

  14. Dec 11, 2018

    Mayne Pharma — Marketing Organization

  15. Jul 2, 2019

    Pharmaceutics International, Inc. — Marketing Organization

  16. Jul 2, 2019

    ANDA Repository — Marketing Organization

  17. Jul 2, 2019

    Strides Pharma Science — Marketing Organization

  18. Aug 2, 2019

    Apotex — Marketing Organization

2020s

  1. Sep 1, 2020

    Annora Pharma — Marketing Organization

Indications

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewSep 11, 1992

Chemistry & pharmacology

Loading structure…

SMILES

CCC(C)N1N=CN(C1=O)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(OC[C@H]5CO[C@@](CN6C=NC=N6)(O5)C7=CC=C(Cl)C=C7Cl)C=C4
Mol. weight
705.633 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Parenteral, Topical
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

Yes

Sources

Also known as

  • (alphar,betas)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1h-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
  • (alphar,betas)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1h-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol
  • canditral
  • itraconazol
  • itraconazol
  • itraconazole
  • itraconazole
  • itraconazole
  • itraconazole
  • itraconazole
  • itraconazole
  • itraconazole
  • itraconazole
  • itraconazole
  • itraconazole
  • itraconazole
  • itraconazolum
  • itraconazolum
  • itrizole
  • itrizole (tn)
  • itrizole (tn)
  • onmel
  • onmel
  • oriconazole
  • oriconazole
  • oriconazole
  • oriconazole
  • r-51211
  • r-51211
  • r-51211
  • sporanos
  • sporanos
  • sporanox
  • sporanox
  • sporanox
  • sporanox
  • sporanox i.v.
  • sporanox-pulse
  • sporanox (tn)
  • sporanox (tn)
  • traconal
  • triasporin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07308652Phase 1Feb 9, 2026Boehringer Ingelheim
NCT07261150Phase 3Feb 1, 2026Federal University of Health Science of Porto Alegre, University of Minnesota
NCT07283497Phase 4Dec 15, 2025Mayo Clinic
NCT07242781Phase 1Dec 8, 2025Bristol-Myers Squibb, Celgene
NCT07242703N/ADec 1, 2025Cairo University
NCT07229560Phase 1Nov 30, 2025Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NCT07211425Phase 1Oct 8, 2025Boehringer Ingelheim
NCT07186452Phase 1Sep 30, 2025Jiangsu Hansoh Pharmaceutical Co., Ltd.
NCT07160738Phase 1Sep 22, 2025Pfizer
NCT07070232Phase 1/Phase 2 (Phase 2)Aug 12, 2025Biontech
NCT07134465Phase 1Aug 11, 2025Haisco Pharmaceutical
NCT07069933Phase 2Jul 31, 2025Mansoura University
NCT07056842Phase 1Jul 20, 2025Government of China
NCT07018635Phase 1Jul 16, 2025Incyte
NCT07071532Phase 1Jul 15, 2025AbbVie
NCT07066722Phase 1Jul 7, 2025ViiV Healthcare
NCT06732388Phase 2Jun 2, 2025National Cancer Institute (NCI), University of Michigan
NCT06942936Phase 1May 28, 2025AstraZeneca, Parexel
NCT06945276Phase 1May 13, 2025National Institute of Allergy and Infectious Diseases (NIAID)
NCT06909162Phase 1May 5, 2025Incyte
Showing 20 of 409 trials
Page 1 / 21

Organizations

Research & Development (246)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Boehringer IngelheimFor profit212112004
PfizerFor profit201922006
AstraZenecaFor profit181822013
Johnson and JohnsonFor profit161541999
Bristol-Myers SquibbFor profit151022014
Eli LillyFor profit131312014
ParexelFor profit11022015
CelgeneFor profit9922016
Janssen Pharmaceutica NVFor profit9441999
Postgraduate Institute of Medical Education and ResearchAcademic/Hospital9942010
RocheFor profit9712013
BayerFor profit8812014
GlaxoSmithKlineFor profit8622006
Hengrui Therapeutics, Inc.For profit8812016
Government of ChinaGovernment7612020
National Institute of Allergy and Infectious Diseases (NIAID)Government7631985
GenentechFor profit6612013
AbbVieFor profit5512023
AstellasFor profit5522008
Enanta PharmaceuticalsFor profit5512017
246 organizations
Page 1 / 13

Marketing (26)

OrganizationOrg typeRelationshipDate
ANDA RepositoryFor profitMKTGJul 2, 2019
Accord ResearchFor profitMKTGMay 26, 2016
AlembicFor profitMKTGDec 13, 2016
AlembicFor profitSYNDec 13, 2016
Alkem Labs LtdFor profitMKTGJun 12, 2017
Amneal PharmaceuticalsFor profitMKTGOct 30, 2015
Annora PharmaFor profitMKTGSep 1, 2020
ApotexFor profitSYNAug 2, 2019
ApotexFor profitMKTGAug 2, 2019
Bristol-Myers SquibbFor profitMKTGDec 13, 2016
Johnson and JohnsonFor profitNDA2Dec 6, 1996
Johnson and JohnsonFor profitSYNSep 11, 1992
Johnson and JohnsonFor profitNDASep 11, 1992
Jubilant Innovation Ltd.For profitMKTGFeb 23, 2017
Mayne PharmaFor profitNDA2Dec 11, 2018
Mayne PharmaFor profitMKTGDec 11, 2018
MylanFor profitMKTGJul 20, 2012
NovartisFor profitMKTGMay 28, 2004
Par PharmaceuticalsFor profitMKTGDec 13, 2016
Pharmaceutics International, Inc.For profitMKTGJul 2, 2019
Rising PharmaceuticalsFor profitMKTGDec 13, 2016
SandozFor profitMKTGMay 28, 2004
Sebela PharmaceuticalsFor profitNDA2Apr 29, 2010
Strides Pharma ScienceFor profitMKTGJul 2, 2019
Torrent Pharmaceuticals LimitedFor profitMKTGAug 24, 2018
Zydus Discovery DMCCFor profitMKTGSep 19, 2017